For more information about products within the Pathway Portfolio, please click here for prescribing information

Respiratory

The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.

Each product in the portfolio has its own key offerings, ranging from:

a full range of strengths available¹
a first strength to market¹
simpler dosing which may help some patients with concordance and compliance^1-2
the first brand to market¹

All of which create a wider offering to patients.

Pathway to Partnership:

Trusted Brands:

Bioequivalent to brand originators³
Available from mainline wholesalers

Bespoke Support:

Price guarantee
Individualised rebates on request

Contact a member of our team

Please click here for Combisal^® prescribing information

Combisal^® (salmeterol/fluticasone) inhalers

Combisal^® (salmeterol/fluticasone) is a pressurised metered dose inhaler (pMDI) for the regular treatment of asthma where use of a combination product (long-acting ß2-agonist and inhaled corticosteroid) is appropriate for:

patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short- acting β2 agonist

patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist⁴

Bioequivalent to Seretide^® pMDI (salmeterol/fluticasone) across all three strengths³
Licensed in both children (25μg/50μg) and adults³
Meets the ups and downs of cost-effective asthma management: flexibility and consistency for patients and prescribers, every step of the way

Save up to 55% on the cost of category C (salmeterol/fluticasone pMDI) on the UK Drug Tariff¹

Combisal^® could reduce the average ICS/ICB prescribing cost of salmeterol/fluticasone by an average of £521,958 per annum, saving up to £21.9 million annually across the NHS^5*.

Please find below materials, which you may find useful for your own reference or to assist with your prescribing. If you would like to order printed versions of any of the materials listed below, please click here to contact one of our representatives.

Patient materials

The following materials can be given to patients being prescribed Combisal^®

Patient Tear Off Pad

RightBreathe^® – How to use your Metered dose inhaler

The following RightBreathe^® Training video demonstrates how to use a pressurised metered dose inhaler (pMDI), which can be used with your patients in your clinics⁶.

The video below was created by and is owned by RightBreathe^®. Aspire Pharma is not responsible for the content of the video.

Healthcare professional resources

Peer-to-peer videos

Our three educational peer-to-peer videos are led by two respiratory experts, Dr Mark Levy and Respiratory Pharmacist, Darush Attar-Zadeh. In the following videos they share their thoughts on Pressurised Metered Dose Inhaler (pMDI) and Dry Powder devices.

Inhaler Technique Optimisation

Low Carbon Alternative Inhaler

pMDI vs DPI – Environment

References:

*Average ICS is based on 4 x Moving Quarterly Turnover (MQT) divided by 42 ICS/ICB’s

UK Drug Tariff (accessed October 2024)
Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
Data on file 1010422379 v 4.0 April 2023 Combisal bioequivalence
Combisal^® SmPC (accessed October 2024)
Insypher 10100831045 v 21.0 August 2024, GPPLPD Date Range: May-24 – Jul-24

XLW1010311D2_OCT2024